RT Journal Article
SR Electronic
T1 Outcomes of COVID-19 Vaccination Efforts in Florida from December 14, 2020 to March 15, 2021 on Older Individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.05.21254722
DO 10.1101/2021.04.05.21254722
A1 Rivkees, Scott. A.
A1 Roberson, Shamarial
A1 Blackmore, Carina
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.05.21254722.abstract
AB Per-capita, Florida ranks second in those 65 years of age and older (20.5%) with more than 4,500,000 individuals in this category. COVID-19 vaccine was allocated in a phased roll-out beginning December 14, 2020. Phase 1A included health care personnel with direct patient contact, and residents and staff of nursing homes (NHs) and assisted living facilities (ALFs). Following this initial phase, individuals 65 years of age and older became eligible for vaccination, along with individuals determined by hospital providers to be extremely medically vulnerable to COVID-19. This strategy was based on the desire to most immediately reduce morbidity and mortality, as COVID-19 morbidity and mortality is age-related. Through March 15, 2021, 4,338,099 individuals received COVID-19 vaccine, including 2,431,540 individuals who completed their vaccination series. Of all those vaccinated, 70% were 65 years of age and older, and 63% of those 65 years of age and older. Beginning February 1, 2021, the decline in the number of new cases per week became greater in those 65 years of age and older than those younger. By March 15, 2021, the number of new cases, hospitalizations, and deaths per day for those 65 years of age and older relative to mid-January, were 82%, 80%, and 92% lower respectively. In comparison, the number of new cases, hospitalizations, and deaths per day for those younger than 65 years of age were 70%, 60%, and 87% lower respectively. Reductions in rates in those 65 year of age and older, were thus greater than in those who were younger (p <0.01; Wilcoxon test). These data show that vaccination efforts directed at those 65 years of age and older results in accelerated rates of overall declines in COVID-19 hospitalizations and mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Exempt review. Florida Department of HealthAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in reports posted on the Florida Department of Health website. http://ww11.doh.state.fl.us/comm/_partners/covid19_report_archive/vaccine/vaccine_report_latest.pdf